Claims
- 1. A compound selected from the group having the formula: ##STR122## wherein; A represents an aromatic ring having two of its carbon atoms held mutually with the oxazepine, thiazepine, or diazepine moiety selected from the group consisting of benzene, naphthalene, a quinoline, or a pyridine in any of its four positions, any of the rings optionally substituted by one or two Y radicals selected from the group consisting of halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, amino, loweracylamino, trifluoromethyl, phenyl or phenyl substituted by one to three Y' groups selected from halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, amino, loweracylamino or trifluoromethyl,
- E is selected from oxygen, sulfur or ##STR123## B is selected from oxygen or sulfur, R is selected from the group consisting of hydrogen, loweralkyl, cyclic alkyl containing 3-9 carbon atoms or phenyl-loweralkyl of which phenyl may be optionally substituted by one or two radicals selected from halo, loweralkyl, loweralkoxy, nitro, or trifluoromethyl,
- n is 1, 2 or 3,
- R.sup.4 and R.sup.5 are selected from hydrogen or loweralkyl (1-5C),
- Z is selected from the group consisting of --NR.sup.1 R.sup.2, 1H-pyrazol-1-yl, 1H-imidazol-1-yl, 1H-imidazol-2-yl or 4,5-dihydro-1H-imidazol-2-yl,
- R.sup.1 and R.sup.2 are selected from the group consisting of hydrogen, loweralkyl, cyclic alkyl containing 3-9 carbon atoms, phenyl and phenyl-loweralkyl of which phenyl may be optionally substituted by 1 or 2 radicals selected from halo, loweralkyl, loweralkoxy, nitro, trifluoromethyl or cyano, or R.sup.1 and R.sup.2 taken together with the adjacent nitrogen atom may form a heterocyclic residue selected from the group consisting of 1-azetidinyl, 1-pyrrolidinyl, 2,5-dimethylpyrrolidin-1-yl, 2-methylpyrrolidin-1-yl, 1-piperidinyl, 4-substituted-piperidine-1-yl, 4-[bis-(4-fluorophenyl)methyl]-piperidin-1-yl, 4-morpholinyl, 1-piperazinyl, 4-substituted piperazin-1-yl, 1,2,3,6-tetrahydropyridin-1-yl, 1H-pyrrol-1-yl or 2,5-dihydro-1H-pyrrol-1-yl, the optical isomers thereof and the pharmaceutically acceptable salts thereof with the proviso that when R=H, Z is never a primary or secondary amine and a further proviso that when n=3, Z is not pyrazolyl or imidazolyl.
- 2. The compound of claim 1 which is 2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methyl-7-phenylpyrido[3,2-f]-1,4-oxazepin-5(4H)-one or a pharmaceutically acceptable salt thereof.
- 3. The compound of claim 1 which is 2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methyl-7-phenylpyrido-[3,2-f]-1,4-oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 4. The compound of claim 1 which is 7-amino-2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methyl-1,4-benzoxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 5. The compound of claim 1 which is 7-acetylamino-2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methyl-1,4-benzoxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 6. The compound of claim 1 which is 2-[2-[[[4-(1,1-dimethylethyl)phenyl]methyl]methylamino]ethyl]-2,3-dihydro-4-methylpyrido[3,2-f]-1,4-oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 7. The compound of claim 1 which is 2,3-dihydro-2-[2-[[2-(4-methoxyphenyl)ethyl]methylamino]ethyl]-4-methylpyrido[3,2-f]-1,4-oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 8. The compound of claim 1 which is 2,3-dihydro-2-[2-[[(4-methoxyphenyl)methyl]methylamino]ethyl-4-methylpyrido[3,2-f]-1,4-oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 9. The compound of claim 1 which is 7-chloro-2-[2-(dimethylamino)ethyl]-2,3-dihydro-4,8-dimethylpyrido[3,2-f]-1,4-oxazepin-5(4H)-one or a pharmaceutically acceptable salt thereof.
- 10. The compound of claim 1 which is 7-chloro-2-[2-(dimethylamino)ethyl]-2,3-dihydro-4,8-dimethylpyrido[3,2-f]-1,4-oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 11. The compound of claim 1 which is 2-[2-(1-azetidinyl)ethyl]-7-chloro-2,3-dihydro-4,8-dimethylpyrido[3,2-f]-1,4-oxazepin-5(4H)-one or a pharmaceutically acceptable salt thereof.
- 12. The compound of claim 1 which is 2-[2-(1-azetidinyl)ethyl]-7-chloro-2,3-dihydro-4,8-dimethylpyrido[3,2-f]-1,4-oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 13. The compound of claim 1 which is 2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methyl-7-(trifluoromethyl)-1,4-benzoxazepin-5(4H)-one or a pharmaceutically acceptable salt thereof.
- 14. The compound of claim 1 which is 2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methyl-7-(trifluoromethyl)-1,4-benzoxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 15. The compound of claim 1 which is 2-[2-(1-azetidinyl)ethyl]-2,3-dihydro-4-methyl-7-(trifluoromethyl)-1,4-benzoxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 16. A compound selected from the group having the formula: ##STR124## wherein; A represents an aromatic ring having two of its carbon atoms held mutually with the oxazepine, thiazepine or diazepin moiety selected from the group consisting of benzene, naphthalene, a quinoline or a pyridine in any of its four positions, any of the rings always substituted by one phenyl radical or one phenyl radical substituted by one to three Y' radicals selected from halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, amino, loweracylamino or trifluoromethyl and the A ring optionally substituted by one Y radical selected from halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, amino, loweracylamino, trifluoromethyl or another ##STR125## radical, E is selected from oxygen, sulfur or ##STR126## B is selected from oxygen or sulfur, R is selected from the group consisting of hydrogen, loweralkyl, cyclic alkyl containing 3-9 carbon atoms or phenyl-loweralkyl of which phenyl may be optionally substituted by one or two radicals selected from halo, loweralkyl, loweralkoxy, nitro, or trifluoromethyl,
- n is 1, 2 or 3,
- R.sup.4 and R.sup.5 are selected from hydrogen or loweralkyl (1-5 C),
- Z is selected from the group consisting of --NR.sup.1 R.sup.2, 1H-pyrazol-1-yl, 1H-imidazol-1-yl, 1H-imidazol-2-yl or 4,5-dihydro-1H-imidazol-2-yl,
- R.sup.1 and R.sup.2 are selected from the group consisting of hydrogen, loweralkyl, cyclic alkyl containing 3-9 carbon atoms, phenyl and phenyl-loweralkyl of which phenyl may be optionally substituted by 1 or 2 radicals selected from halo, loweralkyl, loweralkoxy, nitro, trifluoromethyl or cyano, or R.sup.1 and R.sup.2 taken together with the adjacent nitrogen atom may form a heterocyclic residue selected from the group consisting of 1-azetidinyl, 1-pyrrolidinyl, 2,5-dimethylpyrrolidin-1-yl, 2-methylpyrrolidin-1-yl, 1-piperidinyl, 4-substituted piperidine-1-yl, 4-[bis(4-fluorophenyl)methyl]-piperidin-1-yl, 4-morpholinyl, 1-piperazinyl, 4-substituted piperazin-1-yl, 1,2,3,6-tetrahydropyridin-1-yl, 1H-pyrrol-1-yl or 2,5-dihydro-1H-pyrrol-1-yl, the optical isomers thereof and the pharmaceutically acceptable salts thereof with the proviso that when R=H, Z is never a primary or secondary amine and a further proviso that when n=3, Z is not pyrazolyl or imidazolyl.
- 17. A compound selected from the group having the formula: ##STR127## wherein; A represents an aromatic ring having two of its carbon atoms held mutually with the oxazepine, thiazepine or diazepine moiety selected from the group consisting of benzene, naphthalene, a quinoline or a pyridine in any of its four positions, any of the rings always substituted by one phenyl radical or one phenyl radical optionally substituted by one to three Y' groups wherein Y' is selected from the group consisting of halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, loweracylamino, amino or trifluoromethyl,
- E is selected from oxygen, sulfur or ##STR128## B is selected from oxygen or sulfur, R is selected from the group consisting of hydrogen, loweralkyl, cyclic alkyl containing 3-9 carbon atoms or phenyl-loweralkyl of which phenyl may be optionally substituted by one or two radicals selected from halo, loweralkyl, loweralkoxy, nitro, or trifluoromethyl,
- n is 1, 2 or 3,
- R.sup.4 and R.sup.5 are selected from hydrogen or loweralkyl (1-5 C),
- Z is selected from the group consisting --NR.sup.1 R.sup.2, 1H-pyrazol-1-yl, 1H-imidazol-1-yl, 1H-imidazol-2-yl or 4,5-dihydro-1H-imidazol-2-yl,
- R.sup.1 and R.sup.2 are selected from the group consisting of hydrogen, loweralkyl, cyclic alkyl containing 3-9 carbon atoms, phenyl and phenyl-loweralkyl of which phenyl may be optionally substituted by 1 or 2 radicals selected from halo, loweralkyl, loweralkoxy, nitro, trifluoromethyl or cyano, or R.sup.1 and R.sup.2 taken together with the adjacent nitrogen atom may form a heterocyclic residue selected from the group consisting of 1-azetidinyl, 1-pyrrolidinyl, 2,5-dimethylpyrrolidin-1-yl, 2-methylpyrrolidin-1-yl, 1-piperidinyl, 4-substituted-piperidin-1-yl, 4-[bis(4-fluorophenyl)methyl]-piperidin-1-yl, 4-morpholinyl, 1-piperazinyl, 4-substituted-piperazin-1-yl, 1,2,3,6-tetrahydropyridin-1-yl, 1H-pyrrol-1-yl or 2,5-dihydro-1H-pyrrol-1-yl, the optical isomers thereof and the pharmaceutically acceptable salts thereof with the proviso that when R=H, Z is never a primary or secondary amine and a further proviso that when n=3, Z is not pyrazolyl or imidazolyl.
- 18. A process for the preparation of an aromatic oxazepine, thiazepine or diazepine of the formula: ##STR129## wherein; A represents an aromatic ring having two of its carbon atoms held mutually with the oxazepine, thiazepine, or diazepine moiety selected from the group consisting of benzene, naphthalene, a quinoline or a pyridine in any of its four positions, any of the rings optionally substituted by one or two Y radicals selected from the group consisting of halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, loweracylamino, trifluoromethyl, phenyl or phenyl substituted by one to three radicals selected from halo, loweralkyl, loweralkoxy, nitro, loweracylamino, diloweralkylamino or trifluoromethyl,
- E is selected from oxygen, sulfur or ##STR130## B is selected from oxygen or sulfur, R is selected from the group consisting of hydrogen, loweralkyl, cyclic alkyl containing 3-9 carbon atoms, or phenyl-loweralkyl of which phenyl may be optionally substituted by one or two radicals selected from halo, loweralkyl, loweralkoxy, nitro or trifluoromethyl,
- n is 1, 2 or 3,
- R.sup.4 and R.sup.5 are selected from hydrogen or loweralkyl (1-5 C),
- Z is selected from the group consisting of --NR.sup.1 R.sup.2, 1H-pyrazol-1-yl, 1H-imidazol-1-yl, 1H-imidazol-2-yl, or 4,5-dihydro-1H-imidazol-2-yl,
- R.sup.1 and R.sup.2 are selected from the group consisting of hydrogen, loweralkyl, cycloalkyl containing 3-9 carbon atoms, phenyl and phenyl-loweralkyl of which phenyl is optionally substituted by 1 or 2 radicals selected from halo, loweralkyl, loweralkoxy, nitro, trifluoromethyl or cyano, or R.sup.1 and R.sup.2 taken together with the adjacent nitrogen atom may form a heterocyclic residue selected from the group consisting of 1-azetidinyl, 1-pyrrolidinyl, 2,5-dimethylpyrrolidin-1-yl, 2-methyl-pyrrolidin-1-yl, 1-piperidinyl, 4-substituted-piperidine-1-yl, 4-[bis(4-fluorophenyl)methyl]piperidin-1-yl, 4-morpholinyl, 1-piperazinyl, 4-substituted-piperazin-1-yl, 1,2,3,6-tetrahydropyridin-1-yl, 1H-pyrrol-1-yl or 2,5-dihydro-1H-pyrrol-1-yl, and the pharmaceutically acceptable salts thereof with the proviso that when R is hydrogen, Z is never a primary or secondary amine and a further proviso that when n=3, Z is not pyrazol-yl or imidazolyl which comprises the steps of
- Step (1) halogenating a compound of the formula ##STR131## wherein A represents an aromatic ring selected from benzene, naphthalene, a quinoline, or a pyridine in any of its four positions, any of the aromatic rings optionally substituted by one or two Y radicals selected from halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, loweracylamino, trifluoromethyl, phenyl or phenyl substituted by one to three radicals selected from loweralkyl, loweralkoxy, nitro, loweracylamino, diloweralkylamino, halo or trifluoromethyl,
- E is oxygen, sulfur, or ##STR132## R is selected from the group consisting of loweralkyl, cyclic alkyl, containing 3-9 carbon atoms, or phenylloweralkyl of which phenyl may be optionally substituted by one or two radicals selected from halo, loweralkyl, loweralkoxy, nitro or trifluoromethyl,
- R.sup.3 is hydrogen or an acid neutralizing ion and R.sup.4 and R.sup.5 are hydrogen or loweralkyl(1-5 C), and n is one or two, to give a compound of the formula ##STR133## or its free base wherein X is chlorine or bromine and A, E, R, R.sup.4 and R.sup.5, Y and n are the same as the starting values,
- Step (2) fusing a compound prepared in step 1 to give a compound of the formula: ##STR134## wherein A, E, R, R.sup.4, R.sup.5, n, X and Y are as defined in step 1 and A now has two of its carbon atoms held mutually with the oxazepine, thiazepine, or diazepine moiety,
- Step (3) optionally reacting a compound prepared in step 2 with a sulfurizing agent to obtain an ox- or thiazepinethione or diazepinethione of the formula ##STR135## wherein A, E, R, R.sup.4, R.sup.5, n, X and Y are as defined in step 2, Step (4) when required, reacting a compound prepared in step 2 with an alkali-metal cyanide to obtain a compound of the formula ##STR136## wherein A, E, Y, R, R.sup.4, and R.sup.5 are as defined in step 2, Step (5) reacting a halogen compound prepared in steps 2 or 3 with a compound of the formula
- ZH
- wherein Z is selected from --NR.sup.1 R.sup.2, 1H-pyrazol-1-yl, 1H-imidazol-1-yl, 1H-imidazol-2-yl, or 4,5-dihydro-1H-imidazol-2-yl and wherein R.sup.1 and R.sup.2 are selected from hydrogen, loweralkyl, cyclic alkyl containing 3-9 carbon atoms, phenyl and phenyl-loweralkyl of which phenyl may be optionally substituted with 1 or 2 radicals selected from halo, loweralkyl, loweralkoxy, nitro, trifluoromethyl or cyano or R' and R.sup.2 taken together with the adjacent nitrogen atom may form a heterocyclic residue selected from the group consisting of 1-azetidinyl, 1-pyrrolidinyl, 2,5-dimethylpyrrolidin-1-yl, 2-methylpyrrolidin-1-yl, 1-piperidinyl, 4-substituted piperidin-1-yl, 4-morpholinyl, 4-[bis(4-fluorophenyl)methyl]-piperidin-1-yl, 1-piperazinyl, 4-substituted piperazin-1-yl, 1,2,3,6-tetrahydropyridin-1-yl, 1H-pyrrol-1-yl, 2,5-dihydro-1H-pyrrol-1-yl or phthalimidyl to give a compound of the formula ##STR137## wherein A, E, R, R.sup.4, R.sup.5, n and Y are as defined above in step 2, Z is the same as in the ZH group and B is an oxygen or sulfur atom,
- Step (6) optionally reacting a compound prepared in step (5) wherein B is an oxygen with a sulfurizing agent to obtain a compound of the formula ##STR138## wherein A, E, R, R.sup.4, R.sup.5, n, Y and Z are as defined in step 5, Step (7) reducing a cyano compound prepared in step 4 to a primary amine or reacting a phthalimido compound prepared in Step (5) with hydrazine hydrate to give a compound of the formula: ##STR139## wherein A, E, Y and R, R.sup.4, R.sup.5 are the same as in steps 2 and 4, Step (8) when required reacting a primary amine prepared in steps 5 or 7 of the formula ##STR140## wherein A, E, Y, R, R.sup.4, and R.sup.5 are as defined in step 2 with one of the following reactants or sets of reactants:
- (a) formaldehyde and formic acid to give a tertiary dimethylamine,
- (b) a dihalide or alkenedihalide to give a heterocyclic amine,
- (c) a dialdehyde and sodium cyanoborohydride to give a heterocyclic amine,
- (d) equal molar amounts of an aldehyde or ketone and sodium cyanoborohydride with large excess of above primary amine to give a secondary amine,
- (e) equal molar amounts of the primary amine and sodium cyanoborohydride with at least two equivalents of aldehyde or ketone to give a tertiary amine,
- (f) in sequence: trifluoroacetyl chloride, alkyl or phenylalkyl halide, potassium hydride and potassium hydroxide to give a secondary amine
- all products being encompassed by the formula ##STR141## wherein A, E, Y, R, R.sup.4, and R.sup.5 are as defined in step 2 and Z is --NR.sup.1 R.sup.2 wherein R.sup.1 and R.sup.2 are loweralkyl, cyclic alkyl containing 3-9 carbon atoms, phenyl and phenyl-loweralkyl, the phenyl of which may be optionally substituted by halo, loweralkyl, loweralkoxy, nitro, trifluoromethyl or cyano or R.sup.1 and R.sup.2 taken together with the adjacent nitrogen may form a heterocyclic residue selected from 1-azetidinyl, 1-pyrrolidinyl, 1-piperidinyl, 2,5-dimethylpyrrolidin-1-yl, 4-substituted piperidin-1-yl, 4-[bis(4-fluorophenyl)-methyl]-piperidin-1-yl, 4-morpholinyl, 1-piperazin-1-yl, 4-substituted-piperazin-1-yl, or 1,2,3,6-tetrahydropyridin-1-yl, 1H-pyrrol-1-yl or 2-methylpyrrolidin-1-yl and sulfurizing the azepinone, thiazepinone or diazepinone to give a corresponding thione,
- Step (9) when required, reacting a benzyl or substituted benzyl compound where Z is a tertiary amine or a non-reactive heterocyclic radical obtained in steps 5, 6, or 8 of the formula ##STR142## wherein A, E, R.sup.4, R.sup.5 and Y are as defined in step 2 and Z is a radical under the definition of Z in Formula I subject to the same provisos given thereunder, Z never being a primary or secondary amine, with sodium and ammonia to give a compound of the formula ##STR143## wherein A, E, R.sup.4, R.sup.5 and Y are as defined above in step 2, (n=1 to 3) and Z is the same as the starting compound in this step,
- Step (10) optionally reacting the free base of any compound prepared in steps 5 to 9 with a pharmaceutically acceptable acid or quaternary forming halide or sulfate to form a pharmaceutically acceptable salt thereof.
- 19. The process of claim 18 wherein Y is phenyl or phenyl substituted by one to three radicals selected from halo, loweralkyl, loweralkoxy, nitro, loweracylamino, diloweralkylamino or trifluoromethyl.
- 20. The process of claim 18 wherein the compound prepared is 2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methyl-7-phenylpyrido[3,2-f]-1,4-oxazepin-5(4H)-one or a pharmaceutically acceptable salt thereof.
- 21. The process of claim 18 wherein the compound prepared is 2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methyl-7-phenylpyrido[3,2-f]-1,4-oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 22. The process of claim 18 wherein the compound prepared is 2-[2-[[[4-(1,1-dimethylethyl)phenyl]methyl]methylamino]ethyl]-2,3-dihydro-4-methylpyrido[3,2-f]-1,4oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 23. The process of claim 18 wherein the compound prepared is 2,3-dihydro-2-[2-[[2-(4-methoxyphenyl)ethyl]methylamino]ethyl]-4-methylpyrido[3,2-f]-1,4-oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 24. The process of claim 18 wherein the compound prepared is 2,3-dihydro-2-[2-[[(4-methoxyphenyl)methyl]methylamino]ethyl]-4-methylpyrido[3,2-f]-1,4-oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 25. The process of claim 18 wherein the compound prepared is 7-chloro-2-[2-(dimethylamino)ethyl]-2,3-dihydro-4,8-dimethylpyrido[3,2-f]-1,4-oxazepin-5(4H)-one or a pharmaceutically acceptable salt thereof.
- 26. The process of claim 18 wherein the compound prepared is 7-chloro-2-[2-(dimethylamino)ethyl]-2,3-dihydro-4,8-dimethylpyrido[3,2-f]-1,4-oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 27. The process of claim 18 wherein the compound prepared is 2-[2-(1-azetidinyl)ethyl]-7-chloro-2,3-dihydro-4,8-dimethylpyrido[3,2-f]-1,4-oxazepin-5(4H)-one or a pharmaceutically acceptable salt thereof.
- 28. The process of claim 18 wherein the compound prepared is 2-[2-(1-azetidinyl)ethyl]-7-chloro-2,3-dihydro-4,8-dimethylpyrido[3,2-f]-1,4-oxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 29. The process of claim 18 wherein the compound prepared is 2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methyl-7-(trifluoromethyl)-1,4-benzoxazepin-5(4H)-one or a pharmaceutically acceptable salt thereof.
- 30. The process of claim 18 wherein the compound prepared is 2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methyl-7-(trifluoromethyl)-1,4-benzoxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
- 31. The process of claim 18 wherein the compound prepared is 2-[2-(1-azetidinyl)ethyl]-2,3-dihydro-4-methyl-7-(trifluoromethyl)-1,4-benzoxazepine-5(4H)-thione or a pharmaceutically acceptable salt thereof.
REFERENCE TO PARENT APPLICATIONS
This application is a continuation-in-part of copending U.S. patent application Ser. No. 746,091 filed June 18, 1985, now U.S. Pat. No. 4,592,866, issued June 3, 1986, which is a continuation-in-part of U.S. application Ser. No. 652,058 filed Sept. 19, 1984, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 527,559 filed Aug. 29, 1983, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 431,500 filed Sept. 30, 1982, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4592866 |
Cale |
Jun 1986 |
|
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
746091 |
Jun 1985 |
|
Parent |
652058 |
Sep 1984 |
|
Parent |
527559 |
Aug 1983 |
|
Parent |
431500 |
Sep 1982 |
|